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Executive summary 
A group of investigators gathered to review the landscape of predictive mathematical modelling of 
RSV intervention programmes, and to identify gaps in knowledge and strategy options being 
explored. The objective was to set an agenda for future modelling and related research, to explore 
possible areas for collaborations, and provide an informed status update for various stakeholders.  
A review of the current literature (5 published) and work in progress (3 studies) reveals a range of 
model structures adopted. However, all but one model is dynamic i.e. they allow for reduced 
circulation of virus due to some form of immunity development (reduced risk of infection or of 
infectivity on infection), hence indirect effects are possible (particularly important in view of the 
marked age-dependence in RSV severity, for example). There is no consensus over the mode of 
development and sustaining of this immunity, which results to structural variation in models (levels 
of exposure / immunity development).  Deterministic and probabilistic individual-based frameworks 
are being adopted, with the latter allowing for explicit household and school structure (and hence 
more explicit vaccination strategies) in addition to age-structure, but with associated costs in data 
needs, complexity and computing time.   
Studies investigate vaccine impact on infant disease through a range of strategies (including passive 
and active, in seronegatives and seropositives). One model addresses elderly disease control. 
Models focus on low- and middle- income countries (LMIC) and high income countries (HIC), though 
setting variety is limited. A singe cost-effectiveness study has been published and one is in progress 
(submitted), both focusing on childhood impact in the high income country setting. 
A summary of model findings is that (i) the impact of strategies targeting infant and early childhood 
disease (hospitalisation) could well be very significant, particularly through post-natal vaccination in 
early or delayed infancy or in annual school vaccination (with less clear picture for maternal 
vaccination), and (ii) this impact may result from a major contribution of indirect protection (a herd 
immunity component). Furthermore, (iii) RSV disease in the elderly might be more effectively 
reduced by preventing infection in school going children (spreaders), again through indirect effects; 
and (iv) strategies for preventing childhood disease may be cost-effective, particularly through 
routine infant vaccination or seasonal infant vaccination, with sensitivity to assumptions of costs 
associated with parents off work for child care. 
The modelling work rests on many assumptions and key unknowns remain. Amongst the most 
important gaps in knowledge are, (i) the mechanism whereby immunity is generated by repeated in 
infection and wanes in the absence of infection; (ii) the role of reinfections as a reservoir of 
transmitters in the community, which will depend on their infectivity and population contact 
structures – neither of which are well defined; (iii) the degree of protection conferred by vaccines to 
infection and to disease, and how this relates to the recipient status with regard to  maternal, 
naturally acquired, passive or vaccine induced antibodies; (iv) the role of antigenic variation and 
evolutionary implications of vaccination, and (v) lack of information on RSV QALY/DALYs and costs in 
LMICs.  
An agenda for activities moving forward was developed. Future modelling work should include (i) 
exploration of influence of reinfection in relation to contact structure; (ii) comparison of model 
structures that incorporate epidemiological and immunological uncertainty; (iii) combined 
immunization strategies (eg maternal and infant); and (iv) cost-effectiveness evaluation for LMICs. 
Additionally, production of a report of the meeting to circulate to stakeholders, publication of a 
review of the landscape of modelling of RSV interventions, and to consider where collaborative eg 
consensus approach might offer benefit and identify possible funding opportunity.   
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Glossary 
 
IBM Individual based model 
ODE Ordinary differential equation  
BWI Boosted waning immunity 
SAI Sequential acquisition of immunity 
LMIC Low / middle income countries 
RAS  Realistic age structured 
RSV  Respiratory syncytial model 
HPEHI High potency extended half-life immunoglobulin 
GAVI Global Alliance for Vaccination and Immunization 
BMGF Bill and Melinda Gates Foundation 
JCVI Joint Committee on Vaccination and Immunization 
WHO World Health Organisation 
MORU Mahidol Oxford Research Unit 
KWTRP KEMRI-Wellcome Trust Research Programme 
NITAG National Immunization Technical Advisory Group 
SAGE WHO Strategic Advisory Group of Experts on immunization  
ICER Incremental cost effectiveness ratio 
CEA Cost effectiveness analysis 
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Preamble 
Respiratory syncytial virus (RSV) is recognised to be the most important viral cause of infant and 
early childhood lower respiratory tract infection (LRTI) worldwide. It is also a significant cause of 
disease and death in the elderly and immunocompromised.  Although the majority of disease and 
death occur in low income and middle income countries (LMIC), RSV is also a recognised problem for 
high income country (HIC) settings.  RSV is perceived as a disease requiring intervention in both 
LMICs and HICs.  
A vaccine to prevent RSV disease has been a long time coming. Presently, the development pipeline 
is healthy with over 60 candidates, and 15 or so in clinical trials. Most major pharmaceutical 
companies and a number of young biotech companies are involved. It is likely that the first vaccine, a 
maternal antibody boosting vaccine, will be licensed within 5-10 years.  Disease prevention through 
use of high potency immunoglobulin is also being considered alongside the ‘vaccine’ option.  
Implementation of vaccination or immunization is challenging due to the complexity of the situation.  
Disease arises in different age groups, with multiple options for vaccine delivery, requiring a range of 
product types.  More fundamentally, RSV epidemiology is complex, not least because many of the 
drivers of infection and disease are highly age- and exposure-dependent. There is also a lack of 
understanding of the importance of antigenic diversity and related evolutionary implications of 
vaccination. 
Given this context, in advance of vaccine licensure, predictive mathematical modelling has an 
important role in examining the potential impact of different intervention programmes on RSV 
disease and to explore the cost-effectiveness of various possible options. The literature already 
includes a number of modelling exercises. The approaches used exhibit considerable diversity of (a) 
RSV epidemiology (b) strategy options (c) target age groups and (d) income settings. 
Currently, WHO are working to produce a road map for the development of RSV 
vaccine/immunization strategies [1], and other major stakeholders including BMGF and GAVI are 
entering the arena. The WHO SAGE has produced early recommendations [2]. However, at present 
there is little in the way of a focused quantitative appraisal of the different options available that 
would be necessary for national recommendation and advisory groups (NITAGs). 
With this background in mind a group of investigators involved in RSV modelling, representative of 
most—though not all—research groups and institutes involved in the field, gathered for a one day 
meeting (see Programme and participants in Appendices 1 and 2) to review, compare and critique 
the current modelling studies, identify work in progress or planned, gaps in RSV knowledge and in 
intervention strategies, and draw up a future research agenda.  
Objectives  
• Review current status of RSV modelling (published, unpublished and in preparation).   
• Identify knowledge gaps relevant to model construction, and in vaccine control options and 
target combinations considered. 
• Set out a research agenda and between-group collaboration based on current plans and new 
ideas from the meeting  
• Produce a modelling status update report for circulation to stakeholders  
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Review of Modelling Studies 
Table 1 provides a summary of models of RSV that explore vaccine intervention strategies (or plan 
to).  This review does not include all modelling work on RSV transmission such as exploring factors 
relating to seasonal variation and antigenic diversity [3-5]  
To date, there are 5 published studies that explore the potential impact of RSV immunization 
programmes; they include both low income (Kenya) and high income (Spain, USA) settings.   
At the meeting we heard reports on published studies and studies in the pipeline. The meeting did 
not have representatives from all currently active RSV modelling groups. Notable omissions were the 
groups led by Alison Galvani (Yale, USA) and Kathryn Glass (ANU, Australia).  A list of the key 
research groups/teams involved in RSV modelling of immunization programmes is given in Appendix 
3.  
Detailed reviews of published work were presented by teams from Manchester University and 
Mahidol Oxford Research Unity (MORU) in Bangkok, and from Bocconi University, Milan, and work in 
progress from teams from KWTRP Kenya/Warwick, and UCL/PHE/LSHTM. Summaries are given in 
the following sub-sections and in Table 1 (models) and Table 2 (vaccine strategy options) 
Published research 
Modelling the impact of delayed infant vaccination in Kenya – herd immunity  
Timothy Kinyanjui (University of Manchester), Graham Medley (LSHTM), James Nokes (KEMRI-
Wellcome Trust, University of Warwick) 
Overview 
Deterministic compartmental fully age structured model for LMIC setting used to explore the 
potential of delayed infant and early childhood vaccination motivated by recognition that vaccines 
for early infants face serious challenges. Identifies significant indirect (herd immunity) effect, with 
optimal impact of (live attenuated) vaccine at 4-10 months of age. 
Model description and summary of findings 
• Model detail: Comprises three sub-models  
(i) Epidemiological:  assumes individuals born into a maternal antibody class; repeated infection 
of susceptible individuals builds immunity (up to third infection), resulting in reduced risk of 
infection, reduced infectivity (duration, infectiousness) and reduced risk of disease. In later form 
this model is referred to as the Sequential Immunity Acquisition (SIA) model.  (ii) Disease: The 
risk of disease is a strongly age-dependent process, which is a key factor leading to the indirect 
benefit (on hospitalisation) arising from vaccination.  (iii) Vaccination: vaccine equivalent to wild 
type infection, ie provides equivalent level of protection for naïve susceptibles (baseline), and 
partial susceptibles (ie those previously recovered from past infection and lost temporary 
resistance). 
• Data:  Model parameter estimation and optimisation arise from rural Kenya, including age-
related disease risk and also the contact matrix which is of two forms - diary and synthetic 
(household occupancy and school mixing). Scaling factor to fit hospitalisation data is estimated.  
• Key findings:  (i) Vaccine impact on paediatric hospitalisation is in large part due to indirect 
effects (also referred to as herd immunity) arising from reduced virus circulation and increased 
age at infection, linked to age-related risk of severe disease. (ii) Delay in delivery of vaccine to 
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age 4-10 months provides optimal impact for all levels of coverage: possible delivery with 9m 
measles vaccine (in LMICs) 
• Shortcomings: structural uncertainty (poor understanding of some epidemiological / 
immunological processes); vaccine features (how would a vaccine compare with natural 
infection; possible boosting of immunity; dosing regimes not included;  only for LMIC setting.  
The role of re-infections, relative to primary infections, in driving RSV transmission dynamics was 
found to differ for different age-related mixing structures. Clarification of this role would reduce 
modelling uncertainty.  
A consensus modelling approach to explore the population level impact of TPPs  
Wurichada Pan-Ngum (MORU Thailand), Timothy Kinyanjui (University of Manchester), James Nokes 
(KEMRI-Wellcome Trust, University of Warwick), Sylvia Taylor, Thierry van Effelterre 
(GlaxoSmithKline), Lisa White (MORU) 
Overview  
Application of two structurally different deterministic compartmental models to explore a range of 
vaccine Target Product Profiles (TPP) on paediatric hospitalisations in the LMIC setting.  Models 
harmonised: same contact structures, disease risks and optimisation. Aim of exercise was to define 
vaccine features that could have most influence on impact taking into account major uncertainty in 
immunity development and loss. Exploration of early infant and maternal vaccine strategies (not 
combined).  Both models yield qualitatively similar predicted impact on RSV hospitalization; most 
influential vaccine features were those leading to indirect benefits (ie reduced infection period and 
infectivity).  
Model description and summary of findings 
• Model detail:  Two models, (i) SAI (described above, Fig.1c) and (ii) boosted waning immunity 
(BWI) (see Fig. 1d) reflect structural uncertainty in modelling acquisition of immunity to RSV: 
previously infected susceptibles can revert to fully susceptible status. The BWI model assumes 
individual born into a maternal antibody protected class, then flow into a primary fully 
susceptible class, and upon infection move to one of the infected classes of differing severity, all 
recovering into a partially susceptible class. Subsequent Infection is then at lower risk and also 
resultant lower disease risk (age and exposure related) with recovery back into the partially 
susceptible class, or the partially susceptible individuals can lose immunity if not infected to flow 
back to the primary susceptible class (albeit of older age with different contact and lower risk of 
disease, than when first infected.)   
• Data:  Parametization and optimisation were harmonised for the two models using data 
primarily for the LMIC setting of Kenya.   
• Vaccine implementation and effects: Multiple dosing up to 3 doses. Replicate the compartments 
for each vaccine dose, then flowing back between vaccine classes to unvaccinated classes (see 
eg Fig1d.) Wide range of vaccine features explored including immunity duration, infectivity and 
duration of infection in vaccine failures, various effects on disease risk. 
• Key finding: Both models predicted significant and qualitatively similar impact (over 10 year 
horizon) of post-natal vaccination at realistic levels of coverage with strong indirect effects, with 
BWI greater impact relative to SIA model. Vaccine features of most influence, consistent for the 
two models, were reduced infectiousness and duration upon infection, ie altruistic effects 
leading to reduced virus circulation in the community. Maternal vaccination was predicted to 
have only modest impact on RSV disease (7-15%) high for the BWI relative to SAI model. 
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• Limitations:  Uncertainty exists in the impact of post-natal vaccination in the presence of 
maternal antibodies or of acquired immunity. Impact of combined maternal and infant 
vaccination not explored.  Assumes a vaccine can be delivered in the first few weeks of life.  
Question and answers 
• Using a synthetic social mixing matrix results in a reduced vaccine impact on hospitalisations 
when compared with results from a diary-based mixing matrix (i.e. vaccine impact result is 
contingent on contact structure and infectiousness of older individuals). Uncertainty of contact 
structure and infectiousness of later infections.  
• Response: Importance of secondary cases depends on contact structure. RSV acts more like a SIR 
infection for diary model (driven by primary cases) and more like a SIRS for synthetic model 
(driven by secondary cases.)  
• Schedule of vaccination – 2, 4, 6 months overcrowds or is new. May not be plausible for some 
settings.  
An individual based model (IBM) structured by household and school for the LMIC setting 
Research team 
Piero Poletti, Alessia Melegaro (Bocconi University, Milan); Stefano Merler (Bruno Kesler 
Foundation, Turin), Piero Manfredi (University of Pisa); Patrick Munywoki and James Nokes (KWTRP, 
Kenya). 
Overview 
A simulation model that tracks individuals of a LMIC population that has contacts structured 
according to realistic household groups, school attendance and the general population.  Sequential 
immunity acquisition (SAI) to RSV is assumed. A wide range of vaccine strategy scenarios are 
explored including maternal, early infant, school, and targeted sibling. Impact on RSV infection was 
assessed, with the key results under realistic coverage assumptions, that (a) maternal vaccination is 
highly dependent upon the duration of maternally derived passive protection, (b) early infant and 
repeated annual primary school vaccination were most effective and (c) household cocooning and 
catch-up least effective.    
Model description and summary of findings 
• Model detail:  An individual based (probability) model of a population of ~200,000 in a LMIC 
setting (Kenya), structured by transmission within households, schools, and general community, 
assuming acquisition of immunity up to second infection.  Individuals born into a maternally 
protected class from which they flow to become primary susceptible, infected and recovered, 
with loss of solid immunity to become partially protected (i.e. less) susceptible and so forth.  
• Data: Bayesian statistical analysis. Model modelled to simulate Kenya household and school data 
and fitted to infection and serological data from within a rural Kenya birth cohort.  
• Vaccine implementation and effects: Maternal vaccine adds duration to existing estimated 
maternal passive protection; post-natal infant at 3 months; primary school entry or annual 
primary school age groups; household sibling vaccine boosting; routine plus campaign catch-up 
(up to age 15 years). 
• Key finding: 40% of infections in infants and children <5 years; 30% of infections among school 
age children; within household infection due to between sibling infection or inter-generational 
and significant proportion introduced by school children.  Routine infant and repeat school age 
vaccination only scenarios able to induce longer term significant impact (10 years). One off 
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campaign and targeted school siblings of transient benefit and minimal benefit, respectively. 
Maternal vaccination simply dependent on duration of addition protection.  
• Limitations:  Modelled infection not disease – and hence impact conservative since not realising 
benefit of age-related risk of disease coupled to indirect effects of reduced transmission. No 
seasonality in transmission. Assumes vaccine effective at boosting previously infected individuals 
(ie susceptible seropositives). 
Questions and answers 
• Vaccine trial - We need to know what immunity can be vaccine induced in seropositive / 
previously infected individuals (IBM model). Prevention or reduction in virus shedding 
• Inclusion of seasonality? 
• Breaking chain strategy – vaccinating elder students. Why not good? 
• No contact matrix – but it’s more a household / synthetic matrix – is this less likely to 
produce major impact (as with Kinyanjui model) 
Modelling work in progress 
Combined household, school and meta-population structured model for Kenya 
Research team 
Sam Brand, James Nokes, Matt Keeling (University of Warwick and KWTRP, Kenya) 
Overview 
An individual based simulation model to explore countrywide transmission and vaccine impact of a 
range of respiratory viruses that takes into account population density heterogeneity, but with 
explicit household and school organisation. The epidemiological sub-model is as for the Kinyanjui SIA 
model. Mobility and population flux data (eg from Google Android or Safaricom mobile phone data) 
will be required to link the meta-populations or Counties in the Kenya setting.  The model structure 
is motivated by (i) observation that models using only age structure fail to capture the ‘spikiness’ of 
RSV time series, and (ii) the likely phylogeny of RSV samples seems to indicate preferential within 
household transmission. The goal is to produce a model capable of including: (a) marked variation in 
the population density across Kenya that may account for spatial and temporal dynamics of RSV, (b) 
explicitly simulate vaccine uptake variation spatially, (c) incorporate sequence data on relatedness of 
virus variants across the country being identified through countrywide ILI/SARI surveillance, and (d) 
explicit modelling of within household "cocoon" vaccination.  
Model description and summary of findings and limitations 
The work is in development stage. The benefits of incorporating household structure into a 
countrywide model is at this stage uncertain – although early results indicate the model can capture 
the temporal ‘spikiness’ of seasonal fluctuations well.   Computationally the model is currently too 
slow.  Constructing the joint distribution of household size and age structure is computationally 
expenses and requires a ‘fix’ – validity? Would it be better to revert from an IBM probabilistic model 
to an ODE (ordinary differential equation) deterministic model? 
 Question and answers 
• A short-cut is used to generate a population with accurate joint distribution of family 
structure and household size. Is this good enough?  Is it the extra effort of an IBM 
worthwhile rather than deterministic ODE? 
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• Importance of distribution of durations, eg duration of protection (exponential decay versus 
equal length for all (step function)). This may influence the model simulations, for example, 
multiple reinfections in the same season – which is not observed. 
• Simulations are slow – needs optimisation. Provide age distribution of household members 
as an input rather than simulate. 
• Effect of heterogeneity in birth rates, demographics? 
• This is RSV specific? Why not generalise to be not RSV specific  
• Additional data – HDSS in Kenya. Urban/Rural + migration 
PHE modelling on RSV 
Overview 
Marc Baguelin gave an overview of the PHE/LSHTM/UCL research programme on RSV.   
The principle aim is to integrate relevant data into a modelling, statistical and economic analysis to 
advise JCVI. Vaccine recommendations are underpinned by incremental cost-effectiveness analysis – 
ICER. 
The team: Marc Baguelin and Richard Pebody (PHE), Katie Atkins (LSHTM), Jasmina Panovska-
Griffiths (UCL), Rachel Reeve UCL (supervised by Richard) and David Hodgson (supervised by Katie, 
Marc, Richard and Jasmina).  Historically driven by PHE (modelling) but Warwick has now become a 
second opinion group.  
Two streams of work – Epidemiology and modelling. Eventually cost-effectiveness analysis. 
• Burden studies using regression modelling / mathematical models / QALY estimate studies / 
CEA 
• Cromer et al, influenza 2014 look in Appendix for RSV contribution (dominant) 
• Reeve et al 2017 contribution of RSV to bronchiolitis, pneumonia etc  
• Hodgson – review of RSV model structure and parameterisation 
• Mathematical modelling – explore passive, direct and indirect strategies 
• Collaboration possible with not-for-profit organisations. 
Modelling the impact and cost-effectiveness of RSV vaccination for England  
Research Team 
David Hodgson (UCL), Jasmina Panovska-Griffiths (UCL), Katie Atkins (LSHTM), Marc Baguelin 
(PHE/LSHTM), Richard Pebody (PHE) 
Overview 
A deterministic compartmental age-structured RSV model in development with the aim of informing 
on what target groups should be vaccinated in England factoring in what price are we willing to pay?  
The model is similar to the SAI model of Kinyanjui but with four rounds of infections leading to the 
highest state of immunity. Three vaccine strategy types are to be explored, ie passive, direct and 
indirect. Focus on infants and elderly. Supporting data arise from related disease burden, QALY 
study, contact pattern and cost studies.  
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Model description and summary of findings and limitations 
Individuals born with maternal antibody protection become susceptible, exposed, infectious or 
asymptomatic and then recover, then with the loss of transient immunity the process SE(AI)RS (with 
two infection states: asymptomatic (A) and symptomatic (I))  process continues taking three further 
exposures to generate the highest level of immunity.  An ODE deterministic model chosen as 
opposed to IBM for two reasons: (i) it is deemed suitable to model the main strategies for 
immunization and can conservatively estimate the effect of household cocooning, and (ii) can be 
calibrated to seasonal RSV data in more easily. Contact structure is based on the POLYMOD UK study 
enhanced by a recently published infant contact study (under-represented in POLYMOD). Output will 
be in the form of Incremental Cost Effectiveness Ratio (ICER) and £/QALY. The strategies to be 
explored:   
1) Passive protection strategies: Antepartum and post-partum (high potency extended half-life) 
2) Direct protection: Infants, elderly 
3) Indirect protection strategies: Cocoon, paediatric 
Questions and answers 
• Why the 4 level structure (others have 2 or 3)?  
• Probability of asymptomatic infection by age?  
• Effect of heterogeneity in birth? 
• How to evaluate Cocoon strategy (parents, children, HH members)? Static vaccination: 
Directly reducing the infant’s force of infection by a percentage—an over-estimate and not 
ideal for public health decision-making; Dynamic: Infant effective contact rate is changed 
and is conservative estimate, but maintains model tractability for calibration; Structural: 
Stratify models by households 
• Cost effectiveness evaluation ICER/QALY?  QALY for RSV not well estimated. QALY loss for 
age-dependent clinical outcomes. Investigatory study being conducted using postal 
questionnaire for households with a child detected positive for RSV at hospital. This study 
will provide QALY estimates for children older than five years and adults. It will also provide 
unvalidated estimates for children less than five (as no validated Quality of Life instrument 
has been developed) 
Cost-effectiveness of vaccinating children against RSV in the UK 
Research Team 
Mark Jit (LSHTM/ PHE), Deborah Cromer (UNSW), AJ Van Hoek (RIVM) 
Overview 
Studies concentrating on health and economic burden of maternal, neonatal or infant immunization 
strategies, motivated by need to inform JCVI, and currently in submission. Analysis is based on 
cohort, rather than dynamic, modelling to explore relative cost-effectiveness.  Results indicate a 
range of strategies would be cost-effective, but benefit is highest for childhood immunization 
compared to maternal or neonatal, and by offering protection just before each seasonal outbreak. 
Needs to be done in other parts of the world. CEA of elderly vaccination in development (AJ van 
Hoek).  
Questions and answers 
• Why is infant immunization of greater benefit than earlier (neonatal / maternal) passive 
immunization? 
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• Model is static – yet we expect prevention of early infection to have indirect impact?  Model 
provides lower bound on the cost effectiveness. Introducing dynamics and herd effects can 
only make it better. 
• Timing of immunization? – Seasonal infant dose eg during winter or just before 
• Burden estimation using regression Cromer et al, J Infect 2014 68(4):363-71); age-
distribution of cases in infants < 6 months. 
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Table 1. Summary of vaccine strategy modelling to date (see structures in Fig.1 appended)  
Investigators Institutions  Modelling description  Setting Focus Strategies Key observations Progress 
Acedo L, 
Villanueva R-J. 
Institute 
Multi-
Disciplinary 
Maths Spain. 
Two age class (<1y; ≥1y) 
deterministic 
compartmental model. 
Homogeneous mixing; no 
change in susceptibility 
from past exposure; no 
maternal passive 
protection. 
HIC, Spain Impact on U1Y 
hospitalisation. 
CEA (vaccine, 
hospitalisation 
and parent work 
costs) 
At the time of 
birth. 
Simple ‘first 
approximation’ model. 
Cost analysis sensitive 
to assumptions of 
days parents off work 
for child care.  
Acedo et al,  
E&I 2010[6] 
Piero Poletti, 
Alessia 
Melegaro 
Bocconi 
University 
Milan,  
KWTRP 
Kenya 
Individual based model 
(IBM) of infection 
transmission, structured by 
household and school. 
Sequential acquisition of 
immunity (2 levels). 
 
LMIC, 
Kenya 
Infant infection. 
Impact on 
Infection not 
disease 
Early infant, 
maternal 
boosting, elder 
siblings (cocoon), 
seasonal primary 
school  delivery 
Impact greatest 
through infant and 
seasonal school 
delivery. Herd 
immunity a significant 
contributor. 
Poletti et al,  
BMC Med 
2015[7] 
Tim Kinyanjui, 
Graham Medley 
Manchester, 
KWTRP, 
Warwick 
(LSHTM) 
Deterministic realistic age-
structured compartmental 
model. Acquisition of 
immunity through 
sequential exposures. Diary 
and synthetic mixing 
matrices - data from Kenya. 
LMIC, 
Kenya 
Impact on 
childhood (U5Y) 
hospitalisation 
Infant, early 
childhood 
Predicts strong 
indirect (herd 
immunity) benefit. 
Delayed infant 
vaccination (4-11m) 
optimal. 
Kinyanjui et al, 
PLOS ONE 
2015[8] 
Pan-Ngum, Tim 
Kinyanjui, James 
Nokes, Lisa 
White 
MORU 
Thailand, 
Manchester, 
KWTRP, GSK 
Two deterministic 
compartmental models 
compared, one with 
permanent (partial) 
immunity the other 
waning.    Uses age-related 
LMIC, 
Kenya 
Impact on U5Y 
hospitalisation. 
Explores 
different 
vaccine TPPs. 
Infant (multi-
dose), maternal 
boosting. 
Impact qualitatively 
similar for both 
modelling structures. 
Increased impact most 
evident for improved 
‘altruistic’ vaccine 
Pan-Ngum et 
al, Vaccine 
2017[9] 
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contact rates specific to 
Kenya. 
properties, ie reduced 
infectivity  
Alexandra 
Hogan, Hannah 
Moore, Kathryn 
Glass 
CSIRO, 
National Uni 
Australia; 
Uni Western 
Australia. 
Compartmental ODE, two 
age classes <12m, 12-23m. 
No maternal M class.  
HIC, 
Australia 
Impact on 
hospitalisation 
U1Y, severe 
cases U2Y. 
Early infant (not 
yet 
implemented). 
Limited strategy 
options given age 
structure and 
absence of M. 
Awaits vaccine 
implementation stage.  
Hogan et al, 
Theo Pop Bio 
2016[3]; 
Moore et al, 
PLOS ONE 
2014.[10] 
Dan Yamin, 
John de 
Vincenzo,  
Alison Galvani 
Yale, USA; 
Uni of Tel 
Aviv, Israel.  
Compartmental age-
stratified ODE model.  
Incorporates (i) infectivity 
changes based on shedding 
data and (ii) social 
distancing effects of 
contact rates in infecteds. 
Uses UK (POLYMOD) 
contact data. 
HIC, USA Impact on U5Y 
and adults + all 
ages 
Annual 
vaccination of 
specified age 
groups (with 
influenza vaccine) 
Vaccination of U5Y 
most efficient for 
children and adults. 
Indirect protection: 
vaccination of U5Y 
more protective to 
adults than adult 
vaccination itself.  
Yamin et al, 
PNAS 2016[11] 
Tim Kinyanjui, 
Pan-Ngum, 
James Nokes, 
Lisa White 
Manchester, 
MORU, 
KWTRP, GSK 
Two deterministic 
compartmental models 
compared, one with 
permanent (partial) 
immunity the other 
boosted waning immunity.    
Uses PHE age-related and 
time series case data for 
E&W. Uses UK (POLYMOD) 
contact data. 
HIC, UK Impact on U5Y 
hospitalisation.  
Explores 
different 
vaccine Target 
Product Profiles 
(TPP). 
Infant, maternal 
boosting. 
Not yet available Draft paper  
David Hodgson, 
Jasmina 
Panovska-
Griffiths, Katie 
Atkins, Marc 
UCL, LSHTM, 
PHE 
Deterministic realistic age-
structured model. 
Acquisition of immunity 
through sequential 
exposures (4 levels). 
HIC, UK Impact on 
children and 
adults. Cost-
effectiveness of 
strategies. ICER 
Maternal/neonat
al passive; direct 
(infant and adult) 
and indirect 
Work in progress In progress 
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Baguelin, 
Richard Pebody 
Contact matrix UK.  QALY 
and  
and £/QALY. 
Advise JCVI. 
(paediatric 
/cocoon) 
Mark Jit, 
Deborah 
Cromer, AJ Van 
Hoek  
LSHTM, PHE, 
UNSW/ 
RIVM 
Cohort (static) model of 
disease prevention.  
HIC, eg 
UK 
Health and 
economic costs. 
Advise JCVI.  
Maternal, 
neonatal and 
infant. 
Each strategy cost-
effective. Infant 
routine vaccination 
most cost-effective – 
better if seasonal.  
Submitted 
Notes.  LMIC, HIC  Low or high income countries; C- cost effectiveness analysis; EA KWTRP Kemri Wellcome Trust Research Programme;  MORU Mahidol 
Oxford Research Unit.  ODE Ordinary Differential Equation; TPPs Target Product Profiles 
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Table 2. Review of vaccine strategy options 
Strategy Description  Vaccine type, 
products, status 
Implementation / 
delivery 
Type of immunity: 
against infection or 
Disease 
Issues 
Maternal 
booster vaccine 
(antepartum)1 
Boost matenal RSV specific 
antibody prior to delivery to 
increase duration of infant 
protection.  
Sub-unit F with 
/without adjuvant eg 
Novavax Nanoparticle, 
Phase 3 pregnant 
women  
ANC attendance. 
With influenza 
vaccine? 
Passive immunity. 
Disease prevention. 
Systemic neutralising 
antibodies.  
Reduced severity 
related to reduced 
transmission => indirect 
protection. 
1. Gestational age at ANC 
presentation  
2. Coverage - Proportion 
attending ANC  
3. Adverse events 
4. Factors affecting transfer 
of maternal Ab 
5. Level of Nt Ab induced 
6. Attitudes of women 
 
High potency 
immunoglobulin 
(post-partum) 
High potency extended half 
life immunization to protect 
infant through early months 
of life / 1st RSV season 
Eg Medi8897, Phase 2 
trials 
BCG vaccination in 
1st week, first dose 
routine eg 6 weeks 
OR  
pre-RSV season 
Passive immunity. 
Disease prevention. 
Systemic neutralising 
antibodies.  
Reduced severity 
related to reduced 
transmission => indirect 
protection.  
1. Interference with wild 
type infection or infant 
vaccination 
2. Low coverage at brith eg 
BCG. 
3. Mechanism for delivery 
at start of RSV season 
 
Routine infant Integrate with routine EPI 
infant schedule 
1. Live attenuated 
vaccines (LAV) eg NIH  
and vectored eg 
Mediimne bovine PIV 
2. Sub-unit 
adjuvanted? 
Routine EPI eg 6, 
10, 14 weeks.  
1. Intranasal 
delivery for LAV.  
2. Oarenteral sub-
unit 
LAV: Acive mucosal in 
seronegatives. Infection 
prevention. Acts like 
wid type infection.  
Inidirect benefit.  
Sub-unit: Prevents 
disease but infecton? 
1. Concerns over type of 
immunity elicited, if not 
LAV.  
2. Over-attenuation to be 
safe. 
3. Efficacy in presence of 
Mat Ab? 
                                                          
1 Possibility also of vaccinating mothers at birth (which is likely a lower efficacy strategy), but could still be a back-up option if the mother was not vaccinated during 
pregnancy. Indirect protection would occur after delay of antibody build up (~2 weeks after birth), breast milk transfer of antibodies only. 
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Delayed infant Delayed vaccination in later 
months in infancy to pretect 
recipeients and reduce 
circulation in community 
(indirect protection / herd 
immunity) 
1. Live attenuated 
vaccines (LAV) eg NIH  
and vectored eg 
Mediimne bovine PIV 
2. Sub-unit 
adjuvanted? 
Eg with measles 
vaccination (9m 
LMIC).  
Seasonal – eg 
before annual 
outbreak.  
LAV: Acive mucosal in 
seronegatives. Infection 
prevention. Acts like 
wid type infection.  
Inidirect benefit. 
Sub-unit: Prevents 
disease but infecton? 
1. Vaccine variant 
tranmsitted to early infant 
2. Unliley to boost exisiting 
antobody unless less 
attenuated 
Catch-up At start of infant routine 
programme vaccine 
campaign to immunizae pre-
school and primary school 
age groups. 
According to age 
group. 
Campaign Aim to reduce 
circulation of virus 
Unknown if would prevent 
infection and hence reduce 
circulation. 
School based Seasonal booster 
vaccination to prevent 
spread to community and 
into households  
Sub-unit with or 
without adjuvant. 
With influenza 
vaccine 
Boost systemic 
immunity. Boost 
mucosal immunity? 
Unknown if would prevent 
infection and hence reduce 
circulation.  
Target chain of 
transmission 
Vaccinate individuals known 
to infect infant and break 
chain of transsmission.  
Sub-unit with or 
without adjuvant. 
Vaccinated elder 
siblings / mother at  
Immunization clinic 
(when infant 
receives EPI 
vaccines) 
Boost systemic 
immunity. Boost 
mucosal immunity? 
Unknown if would prevent 
infection and hence reduce 
circulation.  
Family cocoon Vaccinate family members 
of households with an infant  
Sub-unit with or 
without adjuvant. 
Vaccinated elder 
siblings / mother at  
Immunization clinic 
(when infant 
receives EPI 
vaccines) 
Boost systemic 
immunity. Boost 
mucosal immunity? 
Unknown if would prevent 
infection and hence reduce 
circulation.  
Elderly Protect elderly who are at 
risk of very severe RSV 
reinfection 
Sub-unit with or 
without adjuvant. 
With influenza 
vaccine 
Boost systemic 
immunity.  
Unknown if would prevent 
infection and hence reduce 
circulation. 
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Modelling landscape – findings, challenges, knowledge gaps 
Main findings  
Modelling of RSV immunization strategies is at a nascent stage but there are some distinctive 
findings already. The next year or so will undoubtedly see a significant addition of modelling studies 
and new observations. A summary is given here of the key findings from all studies (Table 1) and not 
only those presented at the meeting. 
1. Focus of modelling. Most studies to date target infection/disease in infants and young children. 
One from the US (Yamin) investigates impact on disease in the elderly.   
2. Impact. Models all predict a significant impact from vaccine strategies targeting 
disease/infection in infants and young children.  
3. Herd immunity. Models in their present structural format (except static cohort model of Jit) do 
suggest a role for both direct protection and indirect benefit from vaccination, at least for post-
natal vaccination, and particularly when the main outcome under focus is hospitalisation. This is 
due to the fact that all models assume some form of protected or reduced susceptibility stage 
post recovery from infection which is recapitulated by vaccination.  In addition, most assume 
marked age-dependence in severe disease, such that even slight increase in the average age at 
infection (first and repeat) would significantly alter the risk (down) of severe disease and 
hospitalisation.  In the US study, school-child vaccination was more effective at preventing 
disease in the elderly than was direct vaccination of the elderly (due to indirect protection). 
Models show that varying assumptions surrounding the effective age-related contact rate 
changes the magnitude of impact of vaccination although the age at which it is optimal to 
vaccinate is less sensitive to these assumptions [8]. 
4. Model structures and structural robustness. There is a wide range of model structure – see 
below. One study explored impact based on fundamentally different understanding of the way 
RSV immunity builds [9] but finds qualitatively similar results on the impact of vaccination.  
5. Cost-effectiveness analysis. Two studies to date report on CEA – one dynamic [6] and one static 
cohort (Jit). Both record vaccination to be cost-effective, though sensitive to costs of time off 
work [6]. Jit indicated QALYs most influenced by non-hospitalised disease, whereas costs most 
influenced by hospitalisation/ICU. 
6. Settings. Modelling based on the demographic structure of LMIC and HIC settings have been 
explored. Thus far there is no clear discrepancy between impact in different settings.  
7. Strategies. A wide range of immunization programmes modelled but rarely in combination (eg 
maternal + infant). See Table 2.  
8. Vaccine design – Target Product Profiles (TPPs). Pan-Ngum [9] study addresses issue of 
influence of vaccine characteristics on impact and finds that features affecting infectivity upon 
infection in vaccines are of importance (follows from herd immunity point above). 
Structure of models  
Considerable variation in model structure exists.  
1. Model structure.  Do we know enough about the natural history of infection in the individual? 
The variety of compartmental structures in models to-date suggests not. How many levels of 
exposure related immunity are required and what is the sensitivity of predicted vaccine impact 
on this choice?  
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2. Dynamic versus static. All but one model described is dynamic, ie changes in numbers getting 
infected feeds back to influence risk of exposure and age at infection. This is particularly 
important for RSV due to if there is an age-dependent disease risk process and if age-mixing is 
heterogeneous. Static models (eg Presented by Jit) can be useful as a first approximation and 
may be a good approximation for a maternal immunization strategy that has a high passive 
protective efficacy. 
3. Deterministic or probabilistic. Models thus far are either ODE or IBM. The former is generally 
used to model large populations and the latter where local extinction may arise and to take 
account of more detail in transmission groups.  IBM models can capture greater degree of 
contact structure but at cost of increased computer resources/time and are generally less 
amenable to model calibration. Models of Poletti and Brand use IBM to capture household and 
school related mixing groups, and are applying them to relatively small populations [7] or 
countrywide Kenya (Brand). 
4. Inclusion of households and schools.   Households are known to be favourable for RSV 
transmission, although there is little information about the importance of schools. Inclusion of 
these social structures in the models enables the modelling of explicitly targeted vaccine 
strategies eg the vaccination of school age siblings or cocooning (either directly through 
methods similar to Brand and Poletti (see 3. above) or indirectly via methods used for cocoon 
modelling [12].)  
5. Age structure. At present not all models include full age range. Most of observed dynamics are 
in the first few years of life and so models can capture this with limited age range. However, to 
address vaccine impact wider age range required to account for indirect effects, age-structured 
contacts, reinfections, and school and elderly vaccination. 
6. Age-related mixing patterns.  Patterns of mixing are (a) structured by age-related contacts from 
diary or synthetic matrices (comprising household occupancy, school attendance and otherwise), 
or b) inherent within model structure into households, school etc. The US study [11] uses UK 
contact data. The relative importance of age-related mixing patterns has not yet been 
established.   
7. Demographic structure and range of settings. Modelling based on the demographic structure of 
LMIC and HIC settings have been explored. The importance of pyramidal versus uniform age 
structure on RSV dynamics and control remains an unknown but where the focus is disease of 
the infant this is unlikely to be an issue. But demography in LMIC may be influential when 
considering elderly – this issue has not yet been addressed. 
8. Seasonality. Current dynamic models use a smooth repetitive oscillation (cosine function) to 
drive seasonal transmission and is supplemented by demography as force of infection varies 
over the year. This forced seasonality is fitted to the model, and does not provide an explanatory 
mechanisms through which there is elevated transmission during RSV peak season. 
9. Antigenic diversity. Not included in any models used to explore the impact of immunization.  
The potential consequences on infection and disease associated with RSV are largely unknown.   
Knowledge gaps  
1. Natural history and epidemiology.  Gaps remain in understanding of the transmission dynamics 
of RSV.  
a. Role of re-infected and asymptomatic individuals in RSV transmission?  Individuals do 
become reinfected but the role of these individuals as drivers of transmission in the 
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population is not known.  First, the infectivity of the reinfected individuals is not fully 
known and second the structure of contact patterns in the community will determine 
what role these reinfections play in the dynamics.  This is shown in the paper by 
Kinyanjui which explores two different contact structures that differ in the relative 
magnitude of school age child mixing. Where school mixing is relative low (diary based) 
then primary infected play a dominant role and where high (synthetic matrix) 
reinfecteds drive transmission. Hence (i) more data are required on mixing structure 
relevant to RSV transmission and (ii) better data on the infectivity of those experiencing 
reinfections is needed (eg Munywoki et al 2015  [13]).  This also suggests that the 
inclusion of virus load profiles for primary, reinfected and asymptomatic cases (as a 
correlate of infectivity) in models as in Yamin et al [11] is warranted. 
b. Contact structure.  Age-related contact rates have been defined from diary based or 
similar studies but tend not to provide detailed structure for the youngest age classes  
(for example the POLYMOD European studies partition in 5 year age bands). This does 
not suit RSV well given that the disease-related risks change dramatically in the first two 
years of life.  To what degree RSV is driven by school age children is unknown and 
dependent on age-related mixing (Munywoki et al 2012[14] study reveals how 
influential they could be).   
c. Seasonality.  The key drivers of seasonal transmission are not well understood.  To what 
degree school children play a role in seasonality is not known. Studies of infectivity and 
contact rates of school age groups would be informative.  
2. Immunity to infection. This is an area of considerable uncertainty. The process of immunity 
development is poorly understood.  Generally, too little attention is placed on immunity to 
infection rather than disease, when the former is fundamental to transmission.  
a. Development and maintenance of immunity.  It is not known to what degree immune 
memory is lost in the absence of boosting (refer to SAI versus BWI models of Pan-Ngum).  
This is interconnected with the role or reinfecteds described above. If RSV is more of a 
SIR type model where the reinfecteds play little role (ie they are not an important 
infectious reservoir), then vaccination is likely to result in a significant increase in the 
average age at infection and a reduced force of infection. Under this situation whether 
or not boosting is important to maintenance of ‘immunity’ and resultant infectivity on 
reinfection might be of considerable importance to the outcome of an immunization 
programme.  
b. Maternal antibody protection. The relationship between presence or level of maternal 
passive antibody and immunity to infection and disease is poorly understood.  
c. Antigenic diversity.  The influence of antigenic variation and evolution on RSV 
persistence is not well understood and hence the potential implications to vaccine 
impact are hard to ascertain. Role of antigenic diversity in evasion of immunity to 
infection and disease? 
d. Vaccine interaction. How will boosted maternal antibody or high potency extended half-
life immunization interact with post-natal vaccination? 
3. Factors associated with disease. Age and past exposure. The importance of past exposure to the 
risk of disease independent of the effect of age is not fully elucidated.  This has direct relevance 
to the structure of models (ie number of exposure levels). 
21 | P a g e  
RSV modelling meeting 21-03-17 report version 1.4 27/04/2017  
4. Demographic structure.  Little work has yet investigated RSV dynamics and control in relation to 
demographic structure.  
a. Heterogeneity in population density. RSV seasonality is known to vary even within 
countries. This may result from delays in the spread of the virus between foci of higher 
density. To what degree heterogeneity in population density can affect RSV transmission 
patterns and also affect vaccine programme effectiveness or even influence the design 
of control programmes is unknown.  
b. The implications of population age-structure on vaccine impact are not known. The 
proportion of the population in older age groups may influence the impact of strategies 
designed to control disease in the elderly – which needs to be addressed together with 
contact rates between the elderly and other ages in relation to reservoirs of infectivity.  
c. Unknown how different RSV types circulate around communities, populations and 
regions. The interaction between geography and RSV genetics might be critical. 
5. Vaccine induced immunity. Little attention has been placed in models in the way vaccines 
behave (in generating immunity to infection and disease) in comparison to wild type infection 
(Pan-Ngum study explored different scenarios).  
a. Vaccine effectiveness (against reinfection, disease and infectiousness) in the presence of 
maternal antibody or in recovered individuals who are now partially susceptible. 
b. Differences in vaccine effectiveness in relation to vaccine type (live attenuated or sub-
unit;  intranasal versus injected) 
6. Vaccine characteristics. Knowledge of how vaccines work in different sections of the population 
and their safety needs more consideration in modelling studies.  How do vaccines act in the 
presence of maternal antibodies? Will vaccination of seropositive individuals reduce risk of 
reinfection and infectivity?   
7. Cost-effectiveness. QALYs/DALYs in both HIC LMIC setting are unclear. QALY estimates for 
children are difficult to estimate. While instruments for QALY estimates in older children and 
adults exist, QALY estimate, especially for older adults are poorly quantified currently. 
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Agenda for future work 
Next steps – modeling, data and vaccine requirements 
Modelling work  
 The role of reinfected individuals in relation to contact structure and vaccine impact 
 Consensus outcomes for structural forms (eg levels of exposure for immunity development) 
 Combinations of targets for immunization eg maternal and delayed infant 
 Demographic heterogeneity, seasonality and vaccine strategies 
 Incorporating costs into modelling in LMICs 
Epidemiological  
 Contact patterns – focus on early childhood, school age, elderly 
 Infectivity in relation to primary and repeat infection – reinfection reservoir role 
Vaccines 
 Vaccine effect in the presence of maternal antibody or in seropositive susceptibles 
 Does vaccine boosting reduce infection risk? Important for school age and cocoon strategies 
 Infectivity upon reinfection following vaccination? 
 Vaccine trials (i) maternal vaccination / passive immunization in LMICs (ii) follow up of 
vaccinated seropositives (siblings, pregnant women, school ages) 
 Traditional vaccine design: are they adequate to capture efficacy against multiple outcomes? 
 Influence on RSV genetics – strain replacement, evolution of virulence/pathogenicity, etc 
Cost-effectiveness 
 CEA for each major strategy and combinations of strategy. 
 Determination of costs, DALY and CEA in LMIC settings   
Opportunities for collaboration  
 Integration of health economics into models for LMICs – well defined for HIC 
 Joint modelling exercise to explain why important to measure certain values  
 Link to industry (not for PHE) 
 Funding opportunities – which calls coming up? 
Report and review 
 Report of meeting and modeling landscape for stakeholders 
 Review on modelling, data requirements and control strategies 
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Appendices 
Appendix 1. Meeting programme  
RSV Modelling Meeting Programme, Tuesday, 21st March 2017 
Zeeman Institute: SBIDER Centre, Senate House, University of Warwick  
09.30   Arrival - Coffee/Tea 
10:00   Introductions/ Scene setting – James Nokes 
10.15  Modelling work: published, in progress or planned – Tim Kinyanjui 
 MORU/Manchester/Oxford - Tim Kinyanjui (25 min) 
 Bocconi – Alessia Melegaro (Skype) (15 mins) 
 Warwick / KWTRP Kilifi – Sam Brand (15 mins) 
  Coffee/Tea  
 PHE/LSHTM  - Marc Baguelin (15 min) 
 UCL/LSHTM/PHE – Katie Atkins (15 mins) 
 LSHTM – Mark Jit (Skype) (15 min) 
12.15  Modelling landscape: critique – Sam Brand / James Nokes 
 Modeling structures (list) – advantages, disadvantages  
 Challenges: epi / immunity / vaccine understanding, data needs? 
 Main outcomes/conclusions from work so far 
13.00   Lunch  
14:00   Next questions for modelling: round table – Graham Medley / Matt Keeling 
 What’s missing – approaches, strategies and combinations, settings, CEA? 
 What perspective, who needs to know – who is the audience?  
 Consensus, collaborative modelling, synergies and overlap?  
15.15   What do NITAGs/JCVI/SAGE want from modelling? 
15.30  Tea / coffee break 
15.45   Agenda for the way ahead – James Nokes   
 List of modeling work and data requirements 
 Opportunities for collaborations, links eg University, Industry, funders, Govt 
 Funding requirements, opportunities, next steps? 
 Do we need a collective voice – if so how? Summary review to circulate? 
16.30  Finish 
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Appendix 2. List of individuals attending and affiliations 
 
Name Affiliation  Skype Email 
Katie Atkins LSHTM N Katherine.Atkins@lshtm.ac.uk  
Marc Baguelin PHE / LSHTM N Marc.baguelin@lshtm.ac.uk  
Sam Brand Warwick  N S.Brand@warwick.ac.uk   
Mark Jit LSHTM / PHE Y Mark.jit@lshtm.ac.uk   
Matt Keeling Warwick N M.J.Keeling@warwick.ac.uk  
Nelson Kibinge KWTRP / Warwick N NKibinge@kemri-wellcome.org  
Tim Kinyanjui Manchester N Timothymuiruri.kinyanjui@manchester.ac.uk  
Graham Medley LSHTM N Graham.medley@lshtm.ac.uk  
Alessia Melegaro Bocconi, Italy Y Alessia.melegaro@unibocconi.it  
Patrick Munywoki KWTRP, Kenya Y PMunywoki@kemri-wellcome.org  
James Nokes KWTRP / Warwick N Jnokes@kemri-wellcome.org  
Wurichada Pan-Ngum MORU, Bangkok Y Pan@tropmedres.ac  
Jasmina Panovska-Griffiths UCL N Jasmina.panovska-griffiths@lshtm.ac.uk  
Lorenzo Pellis Warwick N L.Pellis@warwick.ac.uk  
Lisa White MORU, Bangkok Y Lisa@tropmedres.ac  
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Appendix 3. Research groups / teams working on RSV immunization strategy 
modelling 
 
Group Research team Affiliations Key  area of interest 
1 Lisa White, 
Wurichada Pan-
Ngum 
 
Timothy Kinyanjui 
 
James Nokes 
Mathematics and Economics 
Modelling (MAEMOD) group, 
Mahidol Oxford Research Unit 
(MORU), Bangkok, Thailand 
Mathematics Institute, University 
of Manchester 
KEMRI-Wellcome Trust Research 
Programme 
Modelling impact of RSV vaccines in 
LMICs (eg Thailand and Kenya). 
Industry link: GSK vaccine TPPs for 
LMIC (Kenya) and HIC (England and 
Wales). 
2 Alessia Melegaro, 
Piero Poletti, 
Stefano Merler, 
Marco Ajelli,  
Piero Mafredi 
 
University of Bocconi, Milan Italy 
 
Bruno Kesler Foundation, Trento, 
Italy 
University of Pisa, Italy 
 
Investigating the impact of 
demographic transition on the 
transmission dynamics of infectious 
diseases 
3 Sam Brand, Matt 
Keeling, James 
Nokes 
 
Ivy Kombe, 
Graham Medley, 
Marc Baguelin 
SBIDER Centre, Zeeman Institute, 
University of Warwick; KEMRI-
Wellcome Trust Research 
Programme 
LSHTM 
RSV vaccine impact modelling for 
LMIC setting (Kenya). 
4 Mark Jit 
Deborah Cromer 
(UNSW)  
AJ van Hoek 
(RIVM) 
PHE / LSHTM 
UNSW, Australia 
 
RIVM, Netherlands 
Cost effectiveness analysis; UK, 
Europe, SE Asia, Africa, Australia.  
5 David Hodgson,  
Jasmina Panovska-
Griffiths, Rachel 
Reeve 
Katie Atkins  
Marc Baguelin, 
Richard Pebody  
 
UCL 
 
 
 
LSHTM 
PHE 
Set of interconnected projects 
addressing epidemiology and cost-
effectiveness of RSV in England: 
disease burden, modelling, QALY 
estimation and CEA. Models of 
passive, direct and indirect strategies. 
Interest in translation LMICs.  
7 Alexandra Hogan 
Kathryn Glass 
Hannah Moore 
Australian National University 
 
University of Western Australia 
Deterministic modelling of RSV for 
Australia 
8 Alison Galvani Yale RSV vaccine control coupled to 
Influenza school strategy USA 
 
 
